Cowen Downgrades Adamas Pharmaceuticals (ADMS) to Market Perform

Cowen analyst Ken Cacciatore downgraded Adamas Pharmaceuticals (NASDAQ: ADMS) from Outperform to Market Perform with a price target of $15.00 (from $30.00).

• "Disclosure that Gocovri Rx trajectory is flattening and that growth for the next several quarters is expected to be erratic is concerning this early in the launch. Reflecting management's removal of their previous qualitative guidance – and therefore lowering the growth trajectory – our corresponding DCF declines to where a downgrade is warranted."

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $9.56 yesterday.

You May Also Be Interested In

• Macquarie Downgrades Roblox Corp. (RBLX) to Neutral
• Guardant Health (GH) PT Raised to $210 at TD Cowen
• Strategy (MSTR) PT Lowered to $435 at Benchmark